| Delta 4–OTHER: investment, 202104 financing round Series A €multi-million closing with addit funding from European Family Office |
2021-04-07 |
| Delta 4–SEVERAL: investment, 202104 financing round Series A €multi-million closing with addit funding from European Family Office |
2021-04-07 |
| Stimit–Dräger: investment, 202104 acquisition of majority share in Stimit AG by Drägerwerk AG & Co KGaA |
2021-04-01 |
| Pyxis Oncology–SEVERAL: investment, 202103 financing round Series B $152m led by Arix Bioscience |
2021-03-30 |
| Cytosurge–Univ Tübingen: genome editing, 202103 collab cell line developm using FluidFM nano-injection for single cell CRISPR gene engineering |
2021-03-24 |
| Formycon–Leukocare: biopharmaceuticals, 202103– collab Master Service Agreem developm stable formulations for biosimilars/biologics of Formycon |
2021-03-24 |
| Indivumed–Live Wire Strategic Communications: public relations, 202103 service existent by Live Wire |
2021-03-18 |
| Amphista Therapeutics–SEVERAL: investment, 202103 financing round Series B £38m ($53m) co-led by Forbion + Gilde Healthcare |
2021-03-17 |
| GenMark–Roche: investment, 202103– acquisition $1.8b recommended cash tender offer at $24.05/share premium of 43% |
2021-03-15 |
| Monte Rosa Therapeutics–Aisling Capital: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Aisling Capital |
2021-03-12 |
| Monte Rosa Therapeutics–Alphabet: investment, 202103 financing round Series C totalling $95m incl existing + co-investor GV |
2021-03-12 |
| Monte Rosa Therapeutics–Amzak Health: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Amzak Health |
2021-03-12 |
| Monte Rosa Therapeutics–Avoro Capital: investment, 202103 financing round Series C totalling $95m incl new + lead investor Avoro Capital Advisors |
2021-03-12 |
| Monte Rosa Therapeutics–BlackRock: investment, 202103 financing round Series C totalling $95m incl new + co-investor BlackRock |
2021-03-12 |
| Monte Rosa Therapeutics–Cambridge Asset Management: investment, 202103 financing round Series C totalling $95m incl existing + co-investor CAM |
2021-03-12 |
| Monte Rosa Therapeutics–Casdin Capital: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Casdin Capital |
2021-03-12 |
| Monte Rosa Therapeutics–Cormorant Asset Management: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Cormorant |
2021-03-12 |
| Monte Rosa Therapeutics–Fidelity: investment, 202103 financing round Series C totalling $95m incl new + co-investor Fidelity Management & Research Co |
2021-03-12 |
| Monte Rosa Therapeutics–HBM: investment, 202103 financing round Series C totalling $95m incl existing + co-investor HBM Healthcare Investments |
2021-03-12 |
| Monte Rosa Therapeutics–New Enterprise Associates: investment, 202103 financing round Series C totalling $95m incl existing + co-investor NEA |
2021-03-12 |
| Monte Rosa Therapeutics–RTW Investments: investment, 202103 financing round Series C totalling $95m incl new + co-investor RTW Investments |
2021-03-12 |
| Monte Rosa Therapeutics–SEVERAL: investment, 202103 financing round Series C $95m led by new investor Avoro Capital Advisors |
2021-03-12 |
| Monte Rosa Therapeutics–Sixty Degree Capital: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Sixty Degree |
2021-03-12 |
| Monte Rosa Therapeutics–T Rowe Price: investment, 202103 financing round Series C totalling $95m incl new + co-investor T Rowe Price Associates Inc |
2021-03-12 |
| Monte Rosa Therapeutics–Versant Ventures: investment, 202103 financing round Series C totalling $95m incl existing + co-investor Versant Ventures |
2021-03-12 |
| Relief Therapeutics–OTHER: investment, 202103 private placement CHF10m with 41.5m shares at CHF0.2412/share with institutional US investor |
2021-03-12 |
| AgomAb Therapeutics–Boehringer: investment, 202103 financing round Series B totalling $74m incl existing + co-investor BIVF |
2021-03-10 |
| AgomAb Therapeutics–SEVERAL: investment, 202103 financing round Series B $74m led by new investor Redmile Group |
2021-03-10 |
| AgomAb Therapeutics–Trophic Communications: public relations, 202103 service existent by Trophic Communications |
2021-03-10 |
| BellaSeno–Akampion: public relations, 202103 service existent by Akampion |
2021-03-10 |
| BellaSeno–Fraunhofer: implant production technology, 202103– collab developm automated resorbable implant production + QC with Fraunhofer IPT |
2021-03-10 |
| BellaSeno–Germany (govt): grant, 202103– KUM-innovativ grant totalling €1.4m tog with Fraunhofer IPT from BMBF |
2021-03-10 |
| BioPhero–Novo Group: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Novo Holdings |
2021-03-09 |
| BioPhero–SEVERAL: investment, 202103 financing round Series A $17m led by DCVC Bio with FMC Ventures + Syngenta Ventures + Novo Holdings |
2021-03-09 |
| BioPhero–Syngenta: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Syngenta Ventures |
2021-03-09 |
| Lophius–Mikrogen: investment, 202103 acquisition of assets + technologies incl takeover of entire team + lab in Regensburg by Mikrogen |
2021-03-08 |
| Exscientia–BlackRock: investment, 202103 financing round Series C extension totalling $40m + closing at total of $100m incl new investor BlockRock |
2021-03-04 |
| Exscientia–SEVERAL: investment, 202103 financing round Series C extension $40m + closing at total of $100m with BlockRock joining existing investors |
2021-03-04 |
| Atai Life Sciences–KCSA Strategic Communications: public relations, 202103 service existent KCSA is media contact |
2021-03-03 |
| Atai Life Sciences–SEVERAL: investment, 202103 financing round Series D $157m co-led by Apeiron + Thiel Capital |
2021-03-03 |
| ActiTrexx–SEVERAL: investment, 202103 financing round Series A €3.5m led by LBBW Venture Capital GmbH |
2021-03-02 |
| Kairos GmbH–Iqvia: investment, 202103 acquisition of Kairos GmbH by Iqvia |
2021-03-01 |
| Silicon Therapeutics–Roivant: investment, 202102– acquisition $450m in shares + milestones by Roivant Sciences ANNOUNCED |
2021-02-26 |
| Tetramer Shop–10x Genomics: investment, 202102 acquisition €na of Tetramer Shop ApS by 10x Genomics Inc |
2021-02-24 |
| Vividion Therapeutics–SEVERAL: investment, 202102 financing round Series C $135m co-led by new investors Logos Capital + Boxer Capital |
2021-02-24 |
| Ginolis–Cellink: investment, 202102–202103 acquisition 100% of Ginolis debt/cash-free for €65.7m with €41.6m in cash + €24.1m in shares |
2021-02-15 |
| Sophia Genetics–Gilmartin Group: public relations, 202102 service existent Gilmartin Group is investor contact |
2021-02-11 |
| InfanDx–Akampion: public relations, 202102 service existent by Akampion |
2021-02-04 |
| Tecan–UgenTec: laboratory automation, 202102– collab product integration of Tecan workstations with FastFinder qPCR-s/w for sale in dx markets |
2021-02-04 |
| Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund |
2021-02-03 |
| Genopis–Wacker: investment, 202102 acquisition of Genopis Inc for $39m in cash + milestones from Helixmith Co Ltd + Medivate Partners LLC |
2021-02-03 |
| Carisma Therapeutics–Cevec: cell line technology, 202102– license €na for use of CAP technology to produce adenovirus vectors for cancer cell therapy |
2021-02-02 |
| Avacta–Adeptrix: MS-based SARS-CoV-2 test, 202101 collab existent developm of BAMS SARS-CoV-2 assay for research + IVD |
2021-01-28 |
| Avacta–Bruker: MS-based SARS-CoV-2 test, 202101– collab developm of BAMS SARS-CoV-2 assay on Bruker MALDI-TOF as IVD test |
2021-01-28 |
| Enthera–Roche: investment, 202101 financing round Series A extension to final closing at €35m with new investor Roche Venture Fund |
2021-01-28 |
| GeneQuine–Brandenburg (govt): grant, 202101 grant €900k from investment bank of federal state Brandenburg |
2021-01-26 |
| GeneQuine–High-Tech Gründerfonds: investment, 202101 financing round Series A totalling €5.4m incl existing + co-investor HTGF |
2021-01-26 |
| GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA |
2021-01-26 |
| GeneQuine–Pacira BioSciences: credit, 202101 convertible loans totalling €2.75m from Pacira + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Pacira BioSciences: investment, 202101 financing round Series A totalling €5.4m incl lead investor Pacira BioSciences |
2021-01-26 |
| GeneQuine–Samum: credit, 202101 convertible loans totalling €2.75m from Pacira BioSciences Inc + Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–Samum: investment, 202101 financing round Series A totalling €5.4m incl co-investor Samum Vermögensverwaltungs GmbH |
2021-01-26 |
| GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences |
2021-01-26 |
| Microcaps–SEVERAL: investment, 202101 seed financing round CHF5m co-led by Helvetica Capital + ZKB |
2021-01-26 |
| Cellvie–Forever Healthy: investment, 202101 seed financing round totalling $5m incl lead investor Kizoo Technology Capital |
2021-01-25 |
| Cellvie–SEVERAL: investment, 202101 seed financing round $5m led by Kizoo Technology Capital |
2021-01-25 |
| CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share |
2021-01-25 |
| i3 Membrane–High-Tech Gründerfonds: investment, 202101 financing round totalling 7-figure € sum inkl existing investor HTGF |
2021-01-25 |
| i3 Membrane–OTHER: investment, 202101 financing round totalling 7-figure € sum incl three private investors |
2021-01-25 |
| i3 Membrane–SEVERAL: investment, 202101 financing round 7-figure € sum from HTGF + three private investors |
2021-01-25 |
| TScan Therapeutics–Novartis: investment, 202101 financing round Series C totalling $100m incl existing investor Novartis Venture Fund |
2021-01-25 |
| TScan Therapeutics–SEVERAL: investment, 202101 financing round Series C $100m incl new investors Black Rock + RA Capital |
2021-01-25 |
| Numares–Bruker: NMR spectroscopy, 202102– collab developm + product integration Axinon platform for metabolomics-based NMR-CDx |
2021-01-21 |
| AdVita Lifescience–Relief Therapeutics: investment, 202001– binding term sheet acquisition 100% of AdVita for €25m in shares + €20m Milestones |
2021-01-20 |
| Biophytis–SEVERAL: investment, 202101– US IPO of ADSs up to $14.5m at Nasdaq |
2021-01-20 |
| Relief Therapeutics–MC Services: public relations, 202101 service existent by MC Services |
2021-01-20 |
| LignoPure–Hamburg (govt): investment, 202101 seed financing round totalling €2.2m incl investor Innovationsstarter Fonds Hamburg GmbH |
2021-01-18 |
| LignoPure–High-Tech Gründerfonds: investment, 202101 seed financing round totalling €2.2m incl investor HTGF |
2021-01-18 |
| LignoPure–SEVERAL: investment, 202101 seed financing round €2.2m from HTGF + IFH + Tanovis AG |
2021-01-18 |
| LignoPure–Tanovis: investment, 202101 seed financing round totalling €2.2m incl investor Tanovis AG |
2021-01-18 |
| IO Biotech–HBM: investment, 202101 financing round Series B totalling €127m incl new + lead investor HBM Healthcare Investments |
2021-01-13 |
| IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments |
2021-01-13 |
| Medigene–LifeSci: public relations, 202101 supply service existent by LifeSci Advisors |
2021-01-13 |
| Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share |
2021-01-12 |
| Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
| Boehringer–Alphabet: quantum computing, 202101–202312 collab research + implementation of quantum computing in pharma RnD with Google Quantum AI |
2021-01-11 |
| Kymab–Sanofi: investment, 202101 acquisition $1.1b upfront + $350m milestones ANNOUNCED |
2021-01-11 |
| Labforward–2mag: investment, 202101 financing round Series B totalling >€5m incl new + co-investor 2mag |
2021-01-11 |
| Labforward–Peppermint: investment, 202101 financing round Series B totalling >€5m incl existing + co-investor Peppermint VenturePartners |
2021-01-11 |
| Labforward–SEVERAL: investment, 202101 financing round Series B >€5m led by Tecan + incl 2mag + Peppermint VenturePartners |
2021-01-11 |
| Labforward–Tecan: investment, 202101 financing round Series B totalling >€5m incl €4m from new + lead investor Tecan resulting in 10% stake |
2021-01-11 |
| Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP |
2021-01-11 |
| Valo Health–Canada (govt): investment, 202101 financing round Series B totalling $190m incl lead investor PSP Investments |
2021-01-11 |
| Valo Health–HBM: investment, 202101 financing round Series B totalling $190m incl new + co-investor HBM Healthcare Investments |
2021-01-11 |
| Valo Health–SEVERAL: investment, 202101 financing round Series B $190m led by PSP Investments |
2021-01-11 |
| Biogen–Cevec: cell line technology, 202101– license €na to Elevecta technology for manufacutring of AAV vectors for gene therapies |
2021-01-08 |
| AmpTec–Merck (DE): investment, 202101 acquisition €na of AmpTec GmbH bei Merck |
2021-01-07 |
| BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund |
2021-01-07 |
| BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital |
2021-01-07 |
| BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al |
2021-01-07 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] No Content Marketing 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
